Table 2.
Univariate and multivariate analyses of risk factors associated with the incidence of all-grade OM in (A) the first cycle and (B) all cycles in all-patient population.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| (A) | ||||
| Age (years) | ||||
| ≥ 65/< 65 | 0.32 (0.07–1.59) | 0.17 | 0.68 (0.12–3.81) | 0.66 |
| Prior treatment history | ||||
| Yes/no | 0.40 (0.11–1.06) | 0.06 | 0.44 (0.12–1.61) | 0.22 |
| Hormonal receptors | ||||
| ER-, PR-positive or both/Negative | 0.93 (0.40–2.16) | 0.86 | Excluded | – |
| HER2 overexpression | ||||
| Positive/negative | 0.94 (0.33–2.66) | 0.90 | Excluded | – |
| BSA (m2) | ||||
| ≥ 1.5/< 1.5 | 0.96 (0.39–2.33) | 0.93 | Excluded | – |
| BMI (kg/m2) | ||||
| ≥ 25/< 25 | 0.51 (0.60–2.69) | 0.16 | 0.77 (0.27–2.17) | 0.61 |
| Alcohol intake (≥ 5 days in a week) | ||||
| Yes/no | 1.10 (0.36–3.42) | 0.86 | Excluded | – |
| Smoking history | ||||
| Current or former/never | 0.59 (0.25–1.37) | 0.22 | Excluded | – |
| Hypoalbuminemia | ||||
| Present/absent | 1.52 (0.65–3.54) | 0.33 | Excluded | – |
| Liver dysfunction | ||||
| Present/absent | 1.52 (0.64–3.60) | 0.34 | Excluded | – |
| Renal dysfunction | ||||
| Present/absent | 1.11 (0.40–3.06) | 0.84 | Excluded | – |
| Implementation of dental oral care | ||||
| Yes/no | 1.46 (0.59–3.62) | 0.42 | Excluded | – |
| Dexamethasone dosage | ||||
| 4 mg/8 mg | 5.78 (2.26–14.75) | 0.0002** | 4.91 (1.82–13.25) | 0.002** |
| (B) | ||||
| Age (years) | ||||
| ≥ 65/< 65 | 0.45 (0.11–1.80) | 0.26 | Excluded | – |
| Prior treatment history | ||||
| Yes/no | 0.45 (0.15–1.39) | 0.16 | 0.43 (0.13–1.47) | 0.18 |
| Hormonal receptors | ||||
| ER-, PR-positive or both/negative | 0.81 (0.35–1.86) | 0.62 | Excluded | – |
| HER2 overexpression | ||||
| Positive/negative | 1.22 (0.44–3.36) | 0.70 | Excluded | – |
| BSA (m2) | ||||
| ≥ 1.5/< 1.5 | 1.34 (0.56–3.24) | 0.51 | Excluded | – |
| BMI (kg/m2) | ||||
| ≥ 25/< 25 | 0.69 (0.29–1.65) | 0.40 | Excluded | – |
| Alcohol intake (≥ 5 days in a week) | ||||
| Yes/no | 0.84 (0.27–2.60) | 0.77 | Excluded | – |
| Smoking history | ||||
| Current or former/never | 0.65 (0.28–1.49) | 0.31 | Excluded | – |
| Hypoalbuminemia | ||||
| Present/absent | 1.67 (0.73–3.83) | 0.23 | Excluded | – |
| Liver dysfunction | ||||
| Present/absent | 1.86 (0.80–4.33) | 0.15 | 2.01 (0.79–5.08) | 0.14 |
| Renal dysfunction | ||||
| Present/absent | 1.40 (0.52–3.78) | 0.51 | Excluded | – |
| Implementation of dental oral care | ||||
| Yes/no | 1.10 (0.46–2.64) | 0.83 | Excluded | – |
| Dexamethasone dosage | ||||
| 4 mg/8 mg | 3.23 (1.36–7.63) | 0.008** | 2.83 (1.17–6.84) | 0.02* |
*P < 0.05, **P < 0.01.
CI confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, BSA body surface area, BMI body mass index.
Liver dysfunction: grade 1 or higher aspartate aminotransferase, alanine aminotransferase, and total bilirubin levels.
Renal dysfunction: creatinine clearance of less than 80 mL/min.
Cutoff of the serum albumin levels is 4.1 g/dL at our facility.